- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04454983
Lipiflow vs iLux Patient Acceptance and Comfort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction Meibomian gland disease (MGD) is increasingly recognized as a primary cause or contributor to tear instability and dry eye disease. Effective management of this disorder often requires meibomian gland expression and clearance. A variety of devices which apply pressure, heat or a combination of both to the glands have been used.
Two such devices that apply heat and pressure simultaneously are commercially available. LipiFlow (JNJ Vision Care) is an automated computer-controlled device that uses vectored thermal (hydraulic) pulsation applied by an activator device placed on the eye between the globe and the eyelids to achieve gland clearance. The iLux System (Alcon) is an operator controlled assisted manual device which applies heat generated by infrared LEDs and expression through cam driven mechanical pressure applied to the lids.
Device Descriptions LipiFlow Thermal Pulsation System
The Lipiflow Thermal Pulsation System is a commercially available device used in the treatment of MGD. It is cleared to be marketed by the United States Food and Drug Administration. The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye.
The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements. The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland. Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid, without damaging the eyelid or delicate structures of the globe. Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages. Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ (VTP) technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content. Vectored heat and adaptive force equalization target the pulse, heat, and pressure on the meibomian glands to maximize effectiveness. Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.
iLux System
The iLux™ System is a medical device commercially available for use by Eye Care Professionals (ECP) to apply localized heat and pressure therapy to a patient's eyelids. It is cleared to be marketed by the United States Food and Drug Administration. The system consists of a handheld instrument coupled to a single-use, sterile disposable component that is positioned to bridge the eyelid. The iLux device allows an ECP to view the eyelid margin through a magnifier, then warm the eyelid tissue to a range of 40 to 42˚C, and then apply force-limited compression to the eyelid in order to express melted meibum from obstructed glands. The iLux System is indicated for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye.
The iLux Instrument is a handheld, electronic instrument used together with the iLux disposable to apply heating and pressure to the eyelid. The Instrument includes electronic circuits that read sensors in the Inner and Outer Eyelid Pads to measure temperatures representative of inner and outer eyelid temperature, respectively. Warming is accomplished using light energy emitted from LEDs in the Instrument. The LEDs are located behind a clear window on the open end of the Shroud. Two wavelengths of light are used: lime-green (568 nm) and near-infrared (850 nm). A mechanism in the Instrument allows the operator to apply pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure applied to the Compression Control button. The force applied to the Compression Control is measured by a sensor in this mechanism. A graphic Screen displays information for operating the Instrument during a treatment.
Study Purpose / Objectives This study is designed to compare patient acceptance, comfort, and preference between two meibomian gland clearing devices. Both devices are exempt from IDE regulations [21 CFR 812.2(c)]. Primary Objective is to compare patient comfort as assessed by Likert-style scale questionnaire following each bilateral procedure. Secondary Objective is to compare overall experience and treatment preference as assessed by Likert-style questionnaire following each bilateral procedure.
Background "Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction" listed on ClincalTrials.gov looked at a 4-week efficacy comparison between the two treatment devices. Pain and discomfort data were collected regarding the two procedures but was not analyzed for significance due to no pre-trial hypothesis. The raw data shows lower pain and discomfort scores immediately following the procedure for the Lipiflow as compared to iLux with similar pre-treatment and one-day post post-treatment scores (Thornhill 2019). There is currently no published research on the patient acceptance, comfort, and preference comparing any meibomian gland emptying devices.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Phoenix Eye Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject can be of any gender or race
- Subject must be 18 years of age or older at the time of informed consent
2. Subject must be able to understand and must sign an Informed Consent that has been approved by an IRB 3. Subject must have confirmed diagnosis of Meibomian Gland Dysfunction 4. Subject must agree to not wear contact lenses the day of the Study visit
Exclusion Criteria:
- History of intraocular or oculoplastic surgery within 6 months of Screening visit
- History of ocular injury or trauma, chemical burns, or limbal stem cell deficiency within 3 months of the Screening visit
- Active ocular infection or active ocular inflammation (including allergic conjunctivitis, vernal or giant papillary conjunctivitis) at time of Screening visit
- History of ocular surface abnormality that may compromise corneal integrity
- History of treatment with LipiFlow or iLux in either eye in the last 6 months
- Allergy to topical proparacaine eye drops
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lipiflow - All Subjects
Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day.
Subjects were randomized to which procedure they received first.
There was a 1-hour wait between procedures.
|
The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements.
The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland.
Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid.
Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages.
Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid.
Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content.
Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.
|
Experimental: iLux - All Subjects
Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day.
Subjects were randomized to which procedure they received first.
There was a 1-hour wait between procedures.
|
The iLux™ System is used to apply localized heat and pressure to a patient's eyelids.
The system consists of a handheld instrument coupled to a single-use, sterile disposable component that is positioned to bridge the eyelid.
The iLux device allows view of the eyelid through a magnifier, then warms the eyelid to 40 to 42˚C, then force-limited compression is applied manually to express the melted meibum from obstructed glands.
Warming is accomplished using light energy emitted from LEDs in the Instrument.
The LEDs are located behind a clear window on the open end of the Shroud.
Two wavelengths of light are used: lime-green (568 nm) and near-infrared (850 nm).
A mechanism in the Instrument allows the operator to apply pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure applied to the Compression Control button.
The force applied to the Compression Control is measured by a sensor in this mechanism.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure Comfort
Time Frame: 5 minutes
|
Likert-scale questionnaire: 1=strongly disagree, 2=disagree, 3=Undecided, 4=Agree, 5=strongly agree - 1 Question
|
5 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure Experience
Time Frame: 5 minutes
|
Likert-scale questionnaire: 1=strongly disagree, 2=disagree, 3=Undecided, 4=Agree, 5=strongly agree - 4 Questions
|
5 minutes
|
Patient Preference
Time Frame: 5 minutes
|
Questionnaire: Lipiflow, iLux, No Preference
|
5 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Arthur B Epstein, OD, Ophthalmic Research Consultants of Arizona
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEC-Sep2019-Lipi-iLux
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionRecruitingDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Singapore National Eye CentreCompleted
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Singapore National Eye CentreCompleted
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
Clinical Trials on Lipiflow Thermal Pulsation System
-
TearScience, Inc.CompletedDry Eye | Meibomian Gland DysfunctionUnited States, Canada
-
TearScience, Inc.CompletedDry Eye Syndrome | BlepharitisUnited States
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataracts | Meibomian Gland Dysfunction (MGD)United States
-
Samsung Medical CenterUnknownDry EyeKorea, Republic of
-
Sight Sciences, Inc.UnknownDry Eye | Meibomian Gland DysfunctionUnited States
-
Azienda Ospedaliero-Universitaria CareggiCompletedCataract | Dry Eye | Surgery--Complications | Meibomian Gland Dysfunction | BlepharitisItaly
-
Alcon ResearchCompletedMeibomian Gland Dysfunction | Evaporative Dry Eye DiseaseUnited States
-
Tear Film Innovations, Inc.CompletedMeibomian Gland DysfunctionUnited States
-
Tauber Eye CenterCompleted
-
Eye Surgeons of IndianaOcular Therapeutix, Inc.CompletedDry Eye SyndromesUnited States